Dr. Ma on Utilizing Zanabrutinib in CLL
Shuo Ma, MD, PhD, discusses the utilization of zanubrutinib in chronic lymphocytic leukemia.
Dr. Ma on Developing Novel Agents in BTK Inhibitor–Resistant CLL
Shuo Ma, MD, PhD, discusses the need to develop novel agents to treat patients with chronic lymphocytic leukemia who develop resistance to BTK inhibitors.
Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL
Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.
Dr. Shuo Ma on Non-Chemotherapy Regimens for Hematologic Malignancies
Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.
Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer
Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer
T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis
2 Clarke Drive Cranbury, NJ 08512